tbuckley/cabot-search huggingface dataset:
Sel1L-Hrd1 ER-associated degradation maintains β cell identity via TGF-β signaling
Authors: Neha Shrestha, Tongyu Liu, Yewei Ji, Rachel B. Reinert, Mauricio Torres, Xin Li, Maria Zhang, Chih-Hang Anthony Tang, Chih-Chi Andrew Hu, Chengyang Liu, Ali Naji, Ming Liu, Jiandie D. Lin, Sander Kersten, Peter Arvan, Ling Qi
Journal: Journal of Clinical Investigation (2020)

β Cell apoptosis and dedifferentiation are 2 hotly debated mechanisms underlying β cell loss in type 2 diabetes; however, the molecular drivers underlying such events remain largely unclear. Here, we performed a side-by-side comparison of mice carrying β cell-specific deletion of ER-associated degradation (ERAD) and autophagy. We reported that, while autophagy was necessary for β cell survival, the highly conserved Sel1L-Hrd1 ERAD protein complex was required for the maintenance of β cell maturation and identity. Using single-cell RNA-Seq, we demonstrated that Sel1L deficiency was not associated with β cell loss, but rather loss of β cell identity. Sel1L-Hrd1 ERAD controlled β cell identity via TGF-β signaling, in part by mediating the degradation of TGF-β receptor 1. Inhibition of TGF-β signaling in Sel1L-deficient β cells augmented the expression of β cell maturation markers and increased the total insulin content. Our data revealed distinct pathogenic effects of 2 major proteolytic pathways in β cells, providing a framework for therapies targeting distinct mechanisms of protein quality control.
Epithelial to mesenchymal markers and clinical outcomes on erlotinib in stage IV non-small cell lung cancer patients.
Authors: Mark Pool, Mary J. Fidler, Sanjib Basu, Brett Mahon, Lela Buckingham, Kelly Kaiser Walters, Marta Batus, Thomas A. Hensing, Jeffrey A Borgia, Philip D. Bonomi
Journal: Journal of Clinical Oncology (2013)

e19117 Background: An epithelial phenotype in NSCLC is associated with improved sensitivity to EGFR tyrosine kinase inhibitors (TKI). The best method to identify this subset is unknown (Richardson Anticancer Research 2012, Byers Clin Cancer Res 2012). This retrospective study correlates E-cadherin (Ecad) and vimentin (vim) immunohistochemistry (IHC) expression with outcomes in advanced NSCLC patients (pts) treated with erlotinib (E). Methods: Advanced NSCLC pts that received E were included if sufficient tumor was available from diagnosis. IHC scores for E-cad and vim were generated by multiplying frequency (0-4) by intensity (0-4). Log Rank was used to correlate IHC expression with progression free and overall survival (PFS, OS). Results were compared to a subset of pts with tissue from primary surgical NSCLC resection who later received E for recurrent disease. Results: 159 advanced NSCLC pts treated with E had tissue from diagnosis and IHC analysis. There was no correlation with PFS or OS on E and high/low vim or Ecad expression. Subtracting the IHC scores (vim minus ecad) created a difference score. A low difference score (n = 62) correlated with prolonged PFS (2.6 vs 1.9 months, p = .014 HR 1.52) compared with a high score, n = 97. Low difference score trended toward prolonged OS (p=.46) 33 of the patients had tissue available from primary surgical resection. The invasive front was examined for membranous E-cad and cytoplasmic vim (Allred score 0-8). Patients with low vim (&lt; 4) and Ecad (&gt;5), n= 19, trended toward prolonged PFS and OS on E compared with patients with high vim (&gt;5) and low Ecad (&lt;6), n=10 (4.2 vs 1.6 months and 15.5 vs 6.5 months, respectively, p=NS). Conclusions: In this retrospective analysis, using unselected, frequently small tissue specimens, the expression of ecad or vim alone by IHC did not correlate with outcomes for E treated patients. A complicated difference score (vimentin score minus ecadherin score) did correlate with PFS on E. Examining EMT markers at the invasive edge of resected NSCLC tumors might more accurately assess EMT activity and its relationship to outcomes when these pts are recommended EGFR-TKIs.
Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19
Authors: Irani Thevarajan, Thi H. O. Nguyen, Marios Koutsakos, Julian Druce, Leon Caly, Carolien E. van de Sandt, Xiaoxiao Jia, Suellen Nicholson, Mike Catton, Benjamin Cowie, Steven Y. C. Tong, Sharon R. Lewin, Katherine Kedzierska
Journal: Nature Medicine (2020)
SPONTANEOUS RESOLUTION OF PROXIMAL LAD THROMBUS AND DISTAL EMBOLI WITH ORAL ANTICOAGULATION AND ANTIPLATELET THERAPY: A CASE OF ENDOGENOUS FIBRINOLYSIS
Authors: Kleanthis Theodoropoulos, Muhammad Ihsan, Mohammed Al-Sadawi, Jonathan Marmur, Alan Feit
Journal: Journal of the American College of Cardiology (2020)
Multiplexed genetic analysis of malignant pleural mesothelioma and the relationship to clinical outcome.
Authors: Takehito Shukuya, Masakuni Serizawa, Masato Abe, Hiroaki Akamatsu, Takaaki Tokito, Hisao Imai, Akira Ono, Tetsuhiko Taira, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Toshiaki Takahashi, Masahiro Endo, Takashi Nakajima, Yasuhiro Koh, Nobuyuki Yamamoto
Journal: Journal of Clinical Oncology (2013)

7582 Background: Genotype-based stratification is essential to improve cancer treatment. We have developed a multiplexed tumor genotyping panel for detecting gene alterations relevant to molecular targeted therapies. We applied this genotyping panel to malignant pleural mesothelioma (MPM) and evaluate the relationship between clinical outcome and gene alterations. Methods: Surgical specimens and tumor biopsies from 40 patients with MPM were collected from 2003 to 2012. Pathological diagnoses were confirmed by immunohistochemistry in addition to HE stain. 37 patients were genotyped with multiplexed tumor genotyping panel developed to assess 9 gene mutations (EGFR, KRAS, BRAF, PIK3CA, NRAS, MEK1, AKT1, PTEN and HER2) and 5 genes amplifications (EGFR, MET, PIK3CA, FGFR1 and FGFR2) using pyrosequencing plus capillary electrophoresis, and qRT-PCR, respectively. Other 3 patients were analyzed by ultra-deep targeted sequencing with next generation sequencer. 5 fusion genes (EML4-ALK, CD74-ROS1, SLC34A2-ROS1, KIF5B-RET and CCDC6-RET) were tested in 2 patients with fresh frozen specimens. Results: Gene alterations were detected in 6 patients (Table shown below). These patients harboring gene alterations showed poorer survival than the patients in whom gene alterations were not detected (median survival time (MST): 583 vs 164 days, log-lank: p=0.009). Moreover, the patients with PIK3CA amplification/mutation showed poorer survival than the patients without PIK3CA amplification/mutation (MST: 583 vs 103 days, log-lank: p=0.031). Conclusions: Gene alterations which could be a target for molecular targeted therapy were detected in MPM. Especially, PIK3CA pathway is a potential target. [Table: see text]
SAFETY AND EFFICACY OF RIVAROXABAN COMPARED WITH WARFARIN IN END-STAGE RENAL DISEASE WITH ATRIAL FIBRILLATION: A META-ANALYSIS
Authors: Hafez Abdullah, Waqas Ullah, Munnam Jafar, Smitha Narayana Gowda, Yasar Sattar, M. Chadi Alraies
Journal: Journal of the American College of Cardiology (2020)
Blockade of β-Catenin–Induced CCL28 Suppresses Gastric Cancer Progression via Inhibition of Treg Cell Infiltration
Authors: Lu Ji, Wei Qian, Liming Gui, Zhongzhong Ji, Pan Yin, Guan Ning Lin, You Wang, Bin Ma, Wei-Qiang Gao
Journal: Cancer Research (2020)

Dysregulation of Wnt/β-catenin signaling is frequently observed in human gastric cancer. Elucidation of the tumor immune microenvironment is essential for understanding tumorigenesis and for the development of immunotherapeutic strategies. However, it remains unclear how β-catenin signaling regulates the tumor immune microenvironment in the stomach. Here, we identify CCL28 as a direct transcriptional target gene of β-catenin/T-cell factor (TCF). Protein levels of β-catenin and CCL28 positively correlated in human gastric adenocarcinoma. β-Catenin-activated CCL28 recruited regulatory T (Treg) cells in a transwell migration assay. In a clinically relevant mouse gastric cancer model established by Helicobacter (H.) felis infection and N-methyl-N-nitrosourea (MNU) treatment, inhibition of β-catenin/TCF activity by a pharmacologic inhibitor iCRT14 suppressed CCL28 expression and Treg cell infiltration in the stomach. Moreover, an anti-CCL28 antibody attenuated Treg cell infiltration and tumor progression in H. felis/MNU mouse models. Diphtheria toxin-induced Treg cell ablation restrained gastric cancer progression in H. felis/MNU-treated DEREG (Foxp3-DTR) mice, clarifying the tumor-promoting role of Treg cells. Thus, the β-catenin-CCL28-Treg cell axis may serve as an important mechanism for immunosuppression of the stomach tumor microenvironment. Our findings reveal an immunoregulatory role of β-catenin signaling in stomach tumors and highlight the therapeutic potential of CCL28 blockade for the treatment of gastric cancer. SIGNIFICANCE: These findings demonstrate an immunosuppressive role of tumor-intrinsic β-catenin signaling and the therapeutic potential of CCL28 blockade in gastric cancer.
SERIAL ECHOCARDIOGRAPHIC EVALUATION OF PATIENTS WITH DEGENERATIVE MITRAL STENOSIS UNDERGOING TAVR
Authors: Anjani Golive, Sanbir Sidhu, Aashish Gupta, Yvonne Gilliland, Jose David Tafur Soto, Daniel Morin, Salima Qamruddin
Journal: Journal of the American College of Cardiology (2020)
Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A North American (NA) multi-institutional experience.
Authors: Lauren Shizue Maeda, Jessica L. Geiger, Kerry J. Savage, Jim Rose, Lauren C. Pinter-Brown, Matthew Alexander Lunning, Jeremy S. Abramson, Nancy Bartlett, Julie Vose, Jacqueline Drape, Lori S. Muffly, Alex McMillan, Andrew M. Evens, Sonali M. Smith, Steven M. Horwitz, Stephen Maxted Ansell, Ranjana Advani
Journal: Journal of Clinical Oncology (2012)

8060 Background: ENKL is a rare and aggressive subtype of peripheral T-cell lymphoma. Due to its geographic predilection there is a paucity of data on clinical experiences from non-Asian countries. The purpose of this study was to analyze characteristics and outcomes of patients (pts) with ENKL identified from major academic centers in NA. Methods: Pts with newly diagnosed CD56+ ENKL were retrospectively identified. Analyses included disease characteristics, ethnicity, therapy, and outcomes. Results: 115 pts (63.5% Caucasian, 20% Asian, 16.5% other) were identified across 10 centers diagnosed between 5/1990-5/2011 (Era 1: pre-2000, n=16; Era 2: 2000-2005, n=45; Era 3: post-2005, n=54). Median age was 52 years (19-88). 75 (65%) had stage I/II disease and were treated with combined modality therapy (CMT) n=48, chemotherapy (CT) n=14 or radiotherapy (RT) n=14. 40 pts had stage III/IV disease and were treated with CT (n=23), CMT (n=12) or RT (n=5). CT regimens used alone or in CMT were either anthracycline-based (n=68) or other (n=29). 63% of stage I/II pts and 40% with stage III/IV achieved complete remission (CR). 30 pts underwent a stem cell transplant (SCT); 14 in first CR and 16 at progression/relapse (autologous, n=21; allogeneic, n=9). Pts with stage I/II disease had a better progression-free survival (PFS) and overall survival (OS) compared with stage III/IV (12 vs 5.2 months (p=0.003) and 41.5 vs 8.9 months (p&lt;0.0001), respectively). For all stages, treatment with CMT compared with CT or RT alone was also associated with better PFS and OS, 18.0 vs 3.9 months (p&lt;0.0001), and 41.5 vs 10.2 months (p=0.002) respectively. Non-anthracycline-based regimens were associated with better PFS (p=0.001) and OS (p=0.045). No survival differences were seen between Asian and non-Asian pts. Conclusions: This series represents one of the largest experiences of ENKL in NA. Our data are consistent with Asian studies in: 1) majority of pts present with early stage disease; 2) overall poor outcome; 3) superiority of CMT and non-anthracycline regimens. Advances in understanding biology and international collaborative efforts are required to improve outcome in this rare entity.
SEX DIFFERENCES IN AORTIC VALVE CALCIFICATION AND CORONARY ARTERY CALCIFICATION IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Gurpreet Singh, E. Mara Vollema, Tea Gegenava, Nina Ajmone Marsan, Victoria Delgado, Jeroen Bax
Journal: Journal of the American College of Cardiology (2020)
Fecal and urinary incontinence impairing social functioning and quality of life among survivors of gynecologic cancers.
Authors: Kameshwarachari Pushpalatha, Dayanand Sharma, Sunesh Kumar, Pramod Kumar Julka
Journal: Journal of Clinical Oncology (2013)

e16511 Background: Fecal and urinary incontinence are late side effects of pelvic radiotherapy and are termed as most bothersome causes for distress and detachment among survivors of gynecological cancers. The present study was conducted to find out the impact of fecal and urinary incontinence on quality of life with regard to psychological, social and sexual functions. Methods: A cross-sectional study was conducted between June 2010 - June 2011 on cohort of 100 advanced cervical cancer patients treated with pelvic radiation of 50.4 Gy in 28 fractions over 5.5 weeks and concurrent cisplatin, followed by intracavitary boost of 15 Gy. By using a questionnaire addressing social, psychological, sexual concerns, data was collected with respect to loss of interest in social parties, travelling, domestic performance, sexual life, personality changes. Results: Fecal incontinence was seen in 17% and urinary incontinence in 28% which affected quality of life (58%). The impact of these symptoms reflected on refraining from participation in social gatherings (20%) and travelling (18%), decreased performance in domestic activities (32%), fear of losing support of spouse and children especially owing to malodour of urine and feces (35%), lack of interest in pursuing sexual intimacy (25%), apathy (18%), fear of disease recurrence (35%), fear of death (42%). Conclusions: Although psychosocial and sexual issues are less openly addressed in the clinics, structured patient-doctor discussion to envisage and demystify longstanding misconceptions concerning sexual function, psychological education by psychotherapists coupled with social support by system-wide dissemination of awareness in the form of pamphlets, books, videos, websites and other visual aids to patients can maintain the quality of life in such patients. Satisfaction regarding discussions on these issues may also vary depending on oncologic specialty clinic, age of the patient and the gender of her oncologist. Timely intervention to minimize these problems would result in significant increase in the followup rates and prolong the survival of the cancer patients.
FERMENTED DAIRY PRODUCTS, GENDER AND 10-YEAR CARDIOVASCULAR DISEASE ONSET. THE MEDIATING EFFECT OF INSULIN RESISTANCE AND HEPATIC STEATOSIS. HIGHLIGHTS FROM THE ATTICA PROSPECTIVE (2002–2012) STUDY
Authors: Matina Kouvari, Demosthenes Panagiotakos, Christina Chrysohoou, Ekavi Georgousopoulou, Dimitrios Tousoulis, Christos Pitsavos
Journal: Journal of the American College of Cardiology (2020)
DIFFERENCES BETWEEN PATIENTS WITH INTERMITTENT CLAUDICATION AND CRITICAL LIMB ISCHEMIA UNDERGOING ENDOVASCULAR INTERVENTION
Authors: Kunal Patel, Farshid Etaee, Yulun Liu, Chirag Patel, Avantika Banerjee, Ishita Tejani, Emmanouil Brilakis, Subhash Banerjee
Journal: Journal of the American College of Cardiology (2020)
HIGH SENSITIVITY TROPONIN VALUES RAPIDLY RULE-OUT MYOCARDIAL INFARCTION AND ALLOW FOR ED DISCHARGE IN A HIGHER RISK PATIENT POPULATION COMPARED TO CONTEMPORARY PRACTICE
Authors: Richard M. Nowak, Robert H. Christenson, Gordon Jacobsen, Fred Apple, James McCord, Alexander Limkakeng, Adam Singer, W. Frank Peacock, Christopher R. DeFilippi
Journal: Journal of the American College of Cardiology (2020)
A NOVEL DEPLOYMENT TECHNIQUE TO ACHIEVE LOW IMPLANTATION DEPTH IN PATIENTS UNDERGOING TRANSFEMORAL-TRANSCATHETER AORTIC VALVE REPLACEMENT WITH SAPIEN-3
Authors: Yasser Sammour, Kinjal Banerjee, Arnav Kumar, Hassan Mehmood Lak, Cameron Incognito, Jay Patel, Manpreet Kaur, Sanchit Chawla, Omar Abdelfattah, Lars G. Svensson, Murat Tuzcu, Grant W. Reed, Rishi Puri, James Yun, Amar Krishnaswamy, Samir R. Kapadia
Journal: Journal of the American College of Cardiology (2020)
PREDICTORS OF ARTIFACT WITH PACEMAKERS AND IMPLANTABLE CARDIOVERTER DEFIBRILLATORS ON CARDIAC MAGNETIC RESONANCE IMAGING: OPTIMIZATION OF PATIENT SELECTION FOR DIAGNOSTIC IMAGE QUALITY
Authors: Mostafa Abozeed, Duygu Kocyigit, Deborah Kwon, Scott D. Flamm, Bruce Wilkoff, Christine Louise Jellis
Journal: Journal of the American College of Cardiology (2020)
UTILIZING MULTIDISCIPLINARY TEAM BASED CARE AND INNOVATIVE APPROACHES TO IMPROVE CARE OF HEART FAILURE PATIENTS IN A SAFETY-NET HOSPITAL
Authors: Faith Works-Fleming, Diane L. Wirth, Leslie H. Marshburn, Michael D. Knauss, Brandi N. Quinn, Amy Bick, Andrea Cafarelli, Elizabeth Choate, Nisha J. Ali, Bibi J. Haniff, Tara Shropshire, Eva Gourrier, Anekwe E. Onwuanyi, Jeff Herald, Florence Fouts, Sweta M. Patel, Modele Ogunniyi
Journal: Journal of the American College of Cardiology (2020)
Abstract 11263: The Pivotal Role of Mitochondrial Transfer in Regenerative Treatment Using Adipose-Derived Mesenchymal Stem Cell for Heart Failure in Rat
Authors: Daisuke Mori, Shigeru Miyagawa, Takayoshi Ueno, Koichi Toda, Takashi Kido, Toru Kuratani, Kotoe Kawai, Hayato Kurata, Hiroyuki Nishida, Yoshiki Sawa
Journal: Circulation (2018)

Background: Mesenchymal stem cell (MSC) has been reported to be one of candidate cells in cell therapy for the ischemic cardiomyopathy. However therapeutic mechanisms of mesenchymal stem cells for ...
IMPACT OF PULMONARY HYPERTENSION IN PATIENTS UNDERGOING TRANSCATHETER MITRAL VALVE REPAIR FOR SECONDARY MITRAL REGURGITATION: THE COAPT TRIAL
Authors: Ori Ben-Yehuda, Bahira Shahim, Shmuel Chen, Mengdan Liu, Bjorn Redfors, Rebecca T. Hahn, Federico M. Asch, Neil J. Weissman, Diego Medvedofsky, Rishi Puri, Samir R. Kapadia, Anna Sannino, Paul A. Grayburn, Saibal Kar, None Kar, Scott Lim, JoAnn Lindenfeld, William Abraham, Michael Mack, Gregg W. Stone
Journal: Journal of the American College of Cardiology (2020)
MITRACLIP 30-DAY READMISSIONS AND IMPACT OF NEXT-DAY DISCHARGE: AN ANALYSIS FROM NATIONWIDE READMISSIONS DATABASE 2016
Authors: Brian Case, Charan Yerasi, Byomesh Tripathi, Yanying Wang, Brian Forrestal, Anees Musallam, Rebecca Torguson, Itsik Ben-Dor, Hector Garcia-Garcia, William S. Weintraub, Toby Rogers, Ron Waksman
Journal: Journal of the American College of Cardiology (2020)
MACHINE LEARNING FOR IDENTIFICATION OF ELECTROCARDIOGRAPHIC MEASURES PREDICTING ATRIAL FIBRILLATION: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)
Authors: Eric Xie, Colin Wu, Mohammad Ostovaneh, Wendy S. Post, Shelby Kutty, Elsayed Soliman, David A. Bluemke, Susan R. Heckbert, Joao A.C. Lima, Bharath Ambale Venkatesh
Journal: Journal of the American College of Cardiology (2020)
Evidence-based review of intrathecal chemotherapy in outcome of patients with leptomeningeal metastasis
Authors: L. R. Rogers, M. Chamberlain, M. Glantz
Journal: Journal of Clinical Oncology (2006)

1529 Background: Intrathecal chemotherapy (ITC) is commonly employed to treat leptomeningeal metastasis (LM). An evidence-based literature review supporting this practice is lacking. We therefore searched the literature for evidence of efficacy of ITC on LM patient outcome in order to provide evidence-based treatment recommendations. Methods: Computer-assisted searches of the Medline and Cochrane Library databases were performed. Only prospective, randomized, controlled trials in which ITC chemotherapy was used to treat LM were selected. Study design, patient characteristics, interventions, and outcome measures were independently compiled by each of the authors using customized data extraction forms. Each article was assigned a class of evidence by each of the authors. Disagreements were resolved by consensus. Results: Five articles met the criteria. Four studies compared different ITC regimens. One compared ITC to controls who did not receive ITC. Study populations included solid tumors (3 [2 of these included lymphoma]), lymphoma only (1), breast cancer only (1). Positive CSF cytology was a requirement for study entry in three trials. In each trial patients were allowed to receive CNS radiation as needed and non-investigational chemotherapy to treat the underlying cancer. Outcome measures included neurological status (5), survival (5), toxicity (5), CSF cytology (4), cause of death (3), time to neurologic progression (3), and quality of life (2). All studies lacked masked outcome assessment, and some suffered from additional design flaws including insufficient size, inequalities in baseline characteristics, inadequate characterization of treatment arms, and poor choice or definition of primary endpoints. Consequently, all studies provided only Class III evidence. Conclusions: There is no Class I or II evidence that ITC improves outcome in patients with LM. Improved quality of life, survival, or time to neurologic progression in treatment responders vs. non-responders in some of these trials provides a weak suggestion that effective therapy improves clinical outcome. Well-designed, adequately powered studies are urgently needed to determine efficacy of ITC in LM. No significant financial relationships to disclose.
Prospective survey study regarding the implementation of new communication skills curriculum for medical oncology trainees.
Authors: Nathan M. Shumway, Erika J. Struble
Journal: Journal of Clinical Oncology (2012)

9058 Background: After a diagnosis of cancer, many patients suffer from anxiety and distress from uncertainty of symptoms, treatments, and prognosis. Clinicians must recognize opportunities to explore concerns. This study assesses oncology trainees’ views about communication with cancer patients before (PRE) and after (POST) a 12 month curriculum. Methods: Medical oncology fellows were surveyed PRE and POST a communication curriculum consisting of case studies and 6 core lectures which included fundamentals, breaking bad news, transitions to palliative care, advanced care planning, conducting family conferences, and discussing treatment options and informed consent. A 5 point Likert-scale was used to measure fellows’ attitudes and comfort regarding communication PRE and POST with questions grouped according to core topics. (≤2 = trainee disagreement, 3=neutral opinion, and ≥ 4 indicated agreement). Results: PRE and POST surveys were completed by 11 and 8 trainees respectively. In PRE 100% felt communication skills were important and 63% believed these skills could be taught. 82% felt there was not enough time during most visits to address emotion. This decreased to 27% in POST. 18% PRE agreed they were comfortable recognizing coping mechanisms versus 100% POST. 45% felt comfortable eliciting values in PRE versus 87.5% POST. Only 1 fellow (9%) felt comfortable addressing futility in PRE versus 25% in POST. The median grouped score for fundamentals increased from 15 to 17 (p=0.016) and median grouped score for advance care plans and DNR increased from 11 to 13(p=0.026). Conclusions: There is a need to improve oncology communication skills. Our curriculum is just one approach. After intervention, the majority of fellows agreed there was enough time to address emotion and felt more comfortable recognizing coping mechanisms and eliciting values. Discussing futility remains difficult for our fellows. All fellows were more comfortable with fundamental communication skills and advance care plans after the curriculum. The extent the curriculum contributed to the change in survey results is unclear. Further research is needed to guide communication education of oncologists.
EVALUATION OF THE CLINICAL UTILITY OF A NOVEL FORMULATION OF FUROSEMIDE DELIVERED SUBCUTANEOUSLY IN PATIENTS PRESENTING WITH EARLY SIGNS OF FLUID OVERLOAD
Authors: Maxwell Eyram Afari, Jaclyn Lemoine, Margaret Michaelian, Argyro Papafilippaki, Lana Tsao
Journal: Journal of the American College of Cardiology (2020)